SeaStar Medical Holding Crecimiento futuro

Future controles de criterios 2/6

Se prevé un crecimiento anual de los beneficios y los ingresos de SeaStar Medical Holding de 24.2% y 176.3% respectivamente, mientras que el BPA crecerá en un 92.9% al año.

Información clave

24.2%

Tasa de crecimiento de los beneficios

92.9%

Tasa de crecimiento del BPA

Crecimiento de los beneficios de Medical Equipment	17.1%
Tasa de crecimiento de los ingresos	176.3%
Rentabilidad financiera futura	n/a
Cobertura de analistas	Low
Última actualización	19 Nov 2024

Actualizaciones recientes sobre el crecimiento futuro

No hay actualizaciones

Recent updates

Previsiones de crecimiento de beneficios e ingresos

NasdaqCM:ICU - Estimaciones futuras de los analistas y datos financieros pasados (USD Millions)
Fecha	Ingresos	Beneficios	Flujo de caja libre	Flujo de caja operativo	Núm. de analistas medio
12/31/2025	1	-21	N/A	N/A	1
12/31/2024	0	-25	N/A	N/A	1
9/30/2024	0	-30	-16	-16	N/A
6/30/2024	N/A	-33	-12	-12	N/A
3/31/2024	N/A	-32	-11	-11	N/A
12/31/2023	N/A	-26	-10	-10	N/A
9/30/2023	N/A	-25	-11	-11	N/A
6/30/2023	N/A	-20	-11	-11	N/A
3/31/2023	N/A	-18	-10	-10	N/A
12/31/2022	N/A	-12	-8	-8	N/A
9/30/2022	N/A	-5	-4	-4	N/A
6/30/2022	N/A	-4	-4	-4	N/A
3/31/2022	N/A	-5	-4	-4	N/A
12/31/2021	N/A	-5	-5	-5	N/A

Previsiones de crecimiento futuro de los analistas

Ingresos vs. Tasa de ahorro: Se prevé que ICU siga sin ser rentable en los próximos 3 años.

Beneficios vs. Mercado: Se prevé que ICU siga sin ser rentable en los próximos 3 años.

Beneficios de alto crecimiento: Se prevé que ICU siga sin ser rentable en los próximos 3 años.

Ingresos vs. Mercado: Se prevé que los ingresos (176.3% al año) de ICU crezcan más rápidamente que los del mercado US (8.9% al año).

Ingresos de alto crecimiento: Se prevé que los ingresos (176.3% al año) de ICU crezcan más rápidamente que un 20% al año.

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

ROE futura: Datos insuficientes para determinar si la rentabilidad financiera de ICU se prevé que sea elevada dentro de 3 años.

SeaStar Medical Holding Crecimiento futuro

Future controles de criterios 2/6

Información clave

Actualizaciones recientes sobre el crecimiento futuro

Recent updates

FDA Grants Breakthrough Device Designation for Seastar Medical’S Selective Cytopheretic Device for Adults Undergoing Chronic Dialysis

SeaStar Medical Holding Corporation Announces Record Monthly Enrollment Achieve in It's Pivotal Adult AKI Trial

Seastar Medical Holding Corporation Enters into Confidential Settlement Agreement and Release with Nuwellis

Seastar Medical Holding Corporation Announces Enrollment in Its Adult Acute Kidney Injury Pivotal Trial Has Exceeded the Halfway Point Toward an Interim Analysis

SeaStar Medical Holding Corporation has filed a Follow-on Equity Offering in the amount of $25 million.

Levi & Korsinsky, LLP Notifies Investors in Seastar Medical Holding Corporation of A Class Action Securities Lawsuit

SeaStar Medical Holding Corporation Announces First Pediatric Patient Treated in A Commercial Setting with FDA-Approved QUELIMMUNE Therapeutic Device

SeaStar Medical Holding Corporation has completed a Follow-on Equity Offering in the amount of $10.000007 million.

SeaStar Medical Holding Corporation has filed a Follow-on Equity Offering in the amount of $10.000007 million.

SeaStar Medical Holding Corporation has filed a Follow-on Equity Offering in the amount of $10.000007 million.

The Schall Law Firm Reminds Class Action Lawsuit Against SeaStar Medical Holding Corporation

SeaStar Medical Holding Provides Notice to the Nasdaq Stock Market Regarding its Possible Violation of Nasdaq Listing Rule 5635(d)(2)

SeaStar Medical Holding Provides Notice to the Nasdaq Stock Market Regarding its Possible Violation of Nasdaq Listing Rule 5635(d)(2)

SeaStar Medical Holding Corporation Finalizes FDA Labeling Requirement for QUELIMMUNE, Paving the Way for First Commercial Sales as Humanitarian Use Device

High number of new and inexperienced directors

SeaStar Medical Holding Announces Compliance Update with Nasdaq Listing Rule 5550(b)(2) and Nasdaq Listing Rule 5550(a)(2)

SeaStar Medical Holding Corporation Announces Board Changes

SeaStar Medical Holding Corporation Approves Class II Director Appointments

SeaStar Medical Holding Corporation, Annual General Meeting, Jun 04, 2024

SeaStar Medical Announces $3.6 Million NIH Grant Award to Study the Selective Cytopheretic Device in Adult Patients with Severe Chronic Heart Failure

SeaStar Medical Announces $3.6 Million NIH Grant Award to Study the Selective Cytopheretic Device in Adult Patients with Severe Chronic Heart Failure

SeaStar Medical Holding Corporation announced delayed annual 10-K filing

Seastar Medical Provides Updates on Enrollment of Adult Pivotal Clinical Study and Commercial Launch of Quelimmune, FDA-Approved in Pediatric Patients

FDA Grants Humanitarian Device Exemption Approval to Seastar Medical’S Selective Cytopheretic Device for Pediatric Acute Kidney Injury

SeaStar Medical Holding Receives Notification from the Nasdaq Listing Qualifications Department Regarding the Company Regains Compliance with the Market Value Rule

SeaStar Medical Holding Corporation has filed a Follow-on Equity Offering in the amount of $9 million.

SeaStar Medical Holding Corporation has filed a Follow-on Equity Offering in the amount of $9 million.

SeaStar Medical Holding Corporation has filed a Follow-on Equity Offering in the amount of $9 million.

SeaStar Medical Holding Corporation Announces Chief Financial Officer Changes

SeaStar Medical Holding Receives Non-Compliance Notice from Nasdaq

SeaStar Medical Holding Corporation Updates Subject Enrollment in its Pivotal Trial with the Selective Cytopheretic Device in Adults with Acute Kidney Injury

SeaStar Medical Holding Corporation Updates Subject Enrollment in its Pivotal Trial with the Selective Cytopheretic Device in Adults with Acute Kidney Injury

SeaStar Medical Holding Receives Notification from the Nasdaq Listing Qualifications Department of the Nasdaq Stock Market

SeaStar Medical Forms Scientific Advisory Board of Pediatric and Adult Clinical Experts

New major risk - Shareholder dilution

U.S. Food and Drug Administration Issues Approvable Letter for SeaStar Medical Holding Corporation's Selective Cytopheretic Device for Pediatric Patients

FDA Grants SeaStar Medical’s Selective Cytopheretic Device Breakthrough Device Designation for Hepatorenal Syndrome

SeaStar Medical Holding Corporation Announces Publication of Case Series of Three Critically Ill Children with Acute Kidney Injury Safely Treated with it's Selective Cytopheretic Device

SeaStar Medical Holding Corporation Enrolls First Patient in NEUTRALIZE-AKI Pivotal Clinical Trial with the Selective Cytopheretic Device in Adults with Acute Kidney Injury

Seastar Medical Holding Receives Nasdaq Staff Deficiency Letter Regarding Non-Compliance with Market Value of Listed Securities Requirements

SeaStar Medical Holding Corporation, Annual General Meeting, Jun 28, 2023

SeaStar Medical Holding Corporation Provides Regulatory Update Related to HDE Application for Pediatric Selective Cytopheretic Device

SeaStar Medical Announces Details of the Selective Cytopheretic Device Pivotal Study in Critically ill Adults with Acute Kidney Injury

Seastar Medical Receives FDA Approval to Begin Study with Selective Cytopheretic Device to Reduce Hyperinflammation in Adults with Acute Kidney Injury

SeaStar Medical Holding Corporation Submits Investigational Device Exemption Application to FDA to Study a Novel Therapy to Reduce Hyperinflammation in Adult Acute Kidney Injury Patients

High number of new directors

Seastar Medical Appoints Rick Barnett as Chairman of the Board of Directors

No independent directors

SeaStar Medical Announces Positive Interim Safety Findings from Ongoing Study Evaluating the Selective Cytopheretic Device (SCD) in Children

Previsiones de crecimiento de beneficios e ingresos

Previsiones de crecimiento futuro de los analistas

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

Descubre empresas en crecimiento